Related Experiment Videos
Paromomycin therapy of endemic amebiasis in homosexual men
Abstract:
A prospective evaluation was made of the therapeutic efficacy of paromomycin, an orally administered, nonabsorbable aminoglycoside, in 114 homosexual men with mild-to-moderate (nondysenteric) intestinal amebiasis. All patients received 25-35 mg/kg daily in three divided doses for seven days. Of the 80 patients with gastrointestinal complaints at the onset of therapy, 55 (80%) of 69 were asymptomatic within four to six weeks after completion of treatment; 11 patients were lost to follow-up. Paromomycin produced long-term eradication of intestinal Entameba histolytica infection in 92% of all men evaluated. The rate of microbiologic cure among patients with symptoms at the onset of therapy was comparable to that among asymptomatic individuals. Paromomycin was well tolerated, with mild diarrhea during therapy the only frequent adverse effect (67% of patients). Thus, paromomycin is an effective alternative to conventional multi-drug therapy for intestinal amebiasis, and it has the advantages of low toxicity, brief duration of therapy, and a high rate of patient compliance.
Insights
Paromomycin effectively treats intestinal amebiasis in men, eradicating Entameba histolytica infection in 92%. This oral medication offers a safe and well-tolerated alternative to traditional multi-drug regimens.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Pharmacology
Background:
- Intestinal amebiasis caused by Entameba histolytica is a significant parasitic infection.
- Mild-to-moderate cases often require effective and well-tolerated therapeutic options.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of paromomycin for intestinal amebiasis.
- To assess the clinical and microbiologic cure rates of paromomycin treatment.
Main Methods:
- Prospective evaluation of 114 homosexual men with mild-to-moderate intestinal amebiasis.
- Oral administration of paromomycin at 25-35 mg/kg daily for seven days.
- Assessment of clinical symptoms and microbiologic eradication of Entameba histolytica.
Main Results:
- Paromomycin achieved long-term eradication of Entameba histolytica in 92% of evaluated patients.
- 80% of patients with initial gastrointestinal complaints became asymptomatic post-treatment.
- Mild diarrhea was the most common adverse effect (67%), indicating good overall tolerability.
Conclusions:
- Paromomycin is an effective and safe oral treatment for intestinal amebiasis.
- It presents advantages of low toxicity, short duration, and high patient compliance compared to multi-drug therapies.
- This nonabsorbable aminoglycoside is a viable alternative for managing intestinal amebiasis.